Saneca wins significant tablet development and manufacturing contract

The agreement includes the manufacture of 600 million enteric, chewable and film-coated tablets.

The agreement, which follows a successful GMP audit held in January 2018, includes the manufacture of 600 million enteric, chewable and film-coated tablets (RX medicines) per year. It will also involve R&D and laboratory analyses related to existing and emerging formulations, as well as technical support in delivery to the Canadian market.

Markus Saal, sales director at Saneca Pharma said: “Pharmascience is a big name in the pharmaceutical industry, so it’s great to work with them on a project of this size.

“Saneca Pharma produces a large number of tablets for customers every year and has a huge amount of expertise, especially in solid dose manufacturing. By delivering both development and manufacturing services, we’re also able to simplify the tech transfer process to commercial production and streamline our customers’ projects, saving time and costs.

“We’re confident we’ll be able to add value to this project by combining our in-depth knowledge and our wide range of capabilities.”

The substantial agreement consists of nine different stock keeping units (SKUs), covering a number of therapeutic areas.

Pierre Plante, sourcing director at Pharmascience said: “Saneca Pharma is well located in Europe and its experience in manufacturing solid dose products was a huge part of the reason we selected them as our outsourcing partner for this project.

“Its comprehensive tech-transfer offering was also interesting for us. We look forward to continuing to develop our partnership with Saneca as we move into 2018.”